Latest news with #ColoSense®
Yahoo
29-04-2025
- Business
- Yahoo
Geneoscopy Sibling Co-founders Named Finalists for EY Entrepreneur Of The Year 2025 Heartland Award
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future ST. LOUIS, April 29, 2025--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that co-founders Andrew Barnell, MBA, and Erica Barnell, M.D., Ph.D., have been named finalists for the Ernst & Young (EY) Entrepreneur Of The Year® 2025 Heartland Award. Entrepreneur Of The Year is one of the preeminent competitive business awards recognizing leaders of high-growth companies that are creating a better future through innovation, purpose, and transformative impact. This recognition places Geneoscopy's co-founders alongside entrepreneurs and leaders in the Heartland region, which includes Minnesota, Kansas, Missouri, Iowa, Nebraska, North Dakota, and South Dakota. "Being named a finalist is a testament to the hard work of Geneoscopy's entire team," said Andrew Barnell, CEO of Geneoscopy. "Erica and I have always focused on building a strong business foundation—scaling our operations, hiring the right people to advance our mission and technology, establishing key partnerships, and setting the stage for long-term growth. We're honored to be recognized by EY among such an inspiring group of entrepreneurs." Erica and Andrew's leadership and vision have been instrumental in Geneoscopy's growth and advancement of non-invasive diagnostics for gastrointestinal health. Through the development of its novel platform for isolating human RNA from stool samples, Geneoscopy has developed FDA-approved ColoSense®, a highly effective screening solution for colorectal cancer. The company is also expanding its diagnostic pipeline to address critical unmet needs in inflammatory bowel disease. "Building Geneoscopy with my brother has been an incredible journey," said Erica Barnell, M.D., Ph.D., Chief Science and Medical Officer of Geneoscopy. "From early research efforts to developing a clinically validated technology, it has been deeply rewarding to see our vision translate into real-world impact for patients." Regional award winners will be announced on Thursday, June 19, during a special celebration in Minneapolis. Finalists become lifetime members of an esteemed community of Entrepreneur Of The Year alumni from around the world. The winners will then be considered by the National judges for the Entrepreneur Of The Year National Awards, which will be presented in November at the annual Strategic Growth Forum®, one of the nation's most prestigious gatherings of high-growth, market-leading companies. About Geneoscopy, Inc. Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit and follow the company on LinkedIn. Sponsors Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, LLC, Marsh USA and SAP. In the Heartland, sponsors also include Twin Cities Business, Padilla and Brillect. About Entrepreneur Of The Year Founded in 1986, Entrepreneur Of The Year has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 60 countries globally. The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum® in November where National finalists and award winners are announced. The overall National winner represents the US at the EY World Entrepreneur Of The Year™ competition. Visit About EY EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets. Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow. EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories. All in to shape the future with confidence. EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit View source version on Contacts Media Andrea SampsonSampson Public Relations Groupasampson@
Yahoo
18-02-2025
- Business
- Yahoo
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences
ST. LOUIS, February 18, 2025--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Patent Trial and Appeal Board (PTAB) has instituted inter partes review (IPR) of U.S. Patent No. 11,970,746 ("the '746 patent") owned by Exact Sciences. After reviewing Geneoscopy's petition, the supporting evidence, and Exact Sciences' arguments in response, the PTAB determined that Geneoscopy has shown a reasonable likelihood of prevailing on its assertion that the challenged claims of Exact Sciences' '746 patent are unpatentable as obvious over the prior art. Previously, the PTAB instituted an IPR to review the claims of another patent ('781 Patent) owned by Exact Sciences based on Geneoscopy's petition challenging the validity of the '781 Patent. Both decisions are publicly available on the PTAB website. "The PTAB's decision to institute an IPR against the '746 patent, following its July 2024 institution of an IPR against the '781 patent, means the PTAB has found it likely that both patents Exact Sciences has asserted in court against Geneoscopy are invalid," said Andrew Barnell, CEO and co-founder of Geneoscopy. "We are confident that the asserted claims of these patents are unpatentable. These decisions reinforce our position and pave the way for Geneoscopy's launch of ColoSense®, which will bring a new colorectal cancer screening option to the market to increase access to effective and convenient testing that has the potential to save lives." Geneoscopy filed its second IPR petition after Exact Sciences alleged infringement of the '746 patent in a lawsuit filed in the U.S. District Court for the District of Delaware. As with the first petition of the '781 patent, Geneoscopy explained that nothing in the '746 patent is inventive, the method is obvious, and the challenged claims are invalid. The PTAB's decision further strengthens Geneoscopy's defenses to Exact Sciences' allegations in the lawsuit. Geneoscopy has also filed a countersuit against Exact Sciences, alleging breach of contract, misappropriation of trade secrets, and various violations of state and federal law. About Geneoscopy, Inc. Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit and follow the company on LinkedIn. View source version on Contacts Media Contact Andrea SampsonSampson Public Relations Groupasampson@
